This program is supported by an independent educational grant from Genentech. This accredited education activity is available to U.S. healthcare professionals only.

Join leading genitourinary cancer experts Dr. Matthew Galsky and Dr. John P. Sfakianos for this accredited, case-based online CME activity focused on the evolving role of circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer (MIBC). Through practical clinical scenarios and expert discussion, faculty will examine how ctDNA can be applied as both a prognostic and predictive biomarker to inform individualized adjuvant treatment decisions and multidisciplinary care coordination. This program also includes a patient advocate, Joy Williams, representing Bladder Cancer Advocacy Network (BCAN).

Accreditation: 1 AMA PRA Category 1 Credit™

Session Overview

Understanding and Applying ctDNA in MIBC Care

This interactive program explores the expanding role of tumor-informed ctDNA testing across the perioperative MIBC care continuum. Using real-world cases, learners will examine how ctDNA results can be interpreted and operationalized to support evidence-based escalation or de-escalation strategies following definitive surgery.

Key topics include:

• Understanding the dual role of ctDNA
• Learners analyze ctDNA as both a prognostic and predictive biomarker, distinguishing retrospective risk stratification from prospective, treatment-guiding applications and assessing how these differences impact clinical decision-making in MIBC.
• Coordinating ctDNA testing across the care continuum
• A case-based discussion highlights effective collaboration between urology, oncology, and advanced practice providers in ordering, processing, and reviewing ctDNA results at appropriate post-surgical timepoints.
• Applying ctDNA results to guide individualized care
• Faculty and learners navigate real-world decisions between adjuvant treatment escalation and active surveillance, emphasizing shared decision-making, patient communication, and multidisciplinary consensus when managing ctDNA conversion or persistently negative findings.

Who Should Attend?

This program is designed for U.S.-based healthcare professionals involved in the management of patients with muscle-invasive bladder cancer, including:

• Community medical oncologists
• Urologists
• Oncology nurse practitioners
• Physician assistants
• Other healthcare professionals interested in muscle-invasive bladder cancer

Faculty

Matthew Galsky, MD

Dr. Galsky is a medical oncologist specializing in genitourinary malignancies, with a primary focus on bladder cancer. His clinical and research interests include biomarker-driven treatment strategies, perioperative and adjuvant therapy decision-making, and the integration of circulating tumor DNA into clinical practice. He has extensive experience translating emerging clinical trial data into practical, multidisciplinary approaches to patient-centered bladder cancer care.

John P. Sfakianos, MD

Dr. Sfakianos is a urologic oncologist specializing in the surgical management of bladder cancer and perioperative care coordination. His clinical expertise includes radical cystectomy, post-surgical risk assessment, and multidisciplinary collaboration to guide adjuvant treatment and surveillance strategies. He has a strong interest in integrating molecular diagnostics, including tumor-informed ctDNA testing, to support individualized decision-making following surgery.

Joy Williams

A patient advocate with the Bladder Cancer Advocacy Network.

Continuing Education Information

This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™. A statement of participation is available for other healthcare professionals.

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclosures

Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.

Matthew Galsky, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Merck, Research Support from Merck, Travel from Pfizer. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Galsky may reference any unlabeled or unapproved uses of products during the presentation. He will disclose to the audience when this discussion takes place.

John P. Sfakianos, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for CG oncology, Johnson & Johnson, Natera, Urogen, Speakers Bureau participant with Natera, Immunity Bio, Urogen. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Galsky may reference any unlabeled or unapproved uses of products during the presentation. He will disclose to the audience when this discussion takes place.

Joy Williams has no relevant financial relationships with ineligible companies to disclose.

CCI staff (Christine Heim), MedAll staff (Gabriele Marija Baltrusyte, Phil McElnay, Judith Lewis, and Gemma Thomas) have no relevant financial relationships with ineligible companies to disclose.

Activity Accreditation for Health Professions

Physicians

1 AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting March 2nd 2026 and will expire on March 2nd 2026.

Estimated time to complete this activity: 60 min